Imaging diseases of the aorta by MRI: a cost-effectiveness analysis of contrast-enhanced studies compared to non-contrast enhanced angiographic studies
© Sonnex et al; licensee BioMed Central Ltd. 2012
Published: 1 February 2012
Non-contrast-enhanced MR angiography (MRA) of the aorta is a robust alternative to using contrast-enhanced (CE) angiography in the imaging of thoracic aortic diseases. What is the cost impact of not using intravenous contrast routinely in thoracic aorta MRA?
Free-breathing, ECG-triggered, navigator-gated 3D segmented steady state free precession (SSFP) MRA is a promising MR technique for imaging the thoracic aorta. We wanted to establish the economic impact of using non-contrast enhanced angiography (non-CEMRA) in our unit compared to the same time period last year when only CEMRA was used.
Over a 3 month period, 22% of referrals to our cardiac MRI unit (Siemens Aera©, Erlangen, Germany) were for diseases of the aorta. These patients were divided into 5 subsets: 1) familial screening (Marfans, Turners, etc), 2) dilatation, 3) follow-up aortic dissection, 4) congenital aortic and valve disease & 5) vasculitis. 80 data sets for patients referred for evaluation of their aorta were examined. These were compared with 80 data sets in patients with aortic disease imaged in a similar period when only CEMRA was available. Clinical evaluation included recording the patients' serum creatinine, correlation with aortic measurements from previous imaging studies and subjective assessment of image quality. Cost analysis included costs of contrast agent, power injector sets and routine consumable costs associated with intravenous access.
The unit price for consumables for thoracic aortic CEMRA was estimated at $140CAD*/patient ($110CAD for Gadolinium and $30CAD for other disposables). Vasculitis patients (group 5) were excluded from both data sets as intravenous contrast was needed for delayed enhancement imaging. No patient was excluded from CE-angiography due to a high serum creatinine (eGFR in all patients ≥ 30mls/min). No patient undergoing non-CEMRA required an additional CEMRA for a non-diagnostic study. We examined 75 data sets in the 'pre-navigator' group and 72 in the 'post-navigator' group. In the pre-navigator group, 50 patients (67%) underwent CEMRA as part of their examination: 9/12 (75%) group 1, 12/28 (43%) group 2, 2/3 (67%) group 3 and 27/32 (84%) group 4. In the post-navigator group, 14 patients (19%) underwent CEMRA: 5/18 (28%) group 1 (268% reduction), 6/31 (19%) group 2 (266% reduction), 1/5 (20%) group 3 (335% reduction) and 5/18 (28%) group 4 (300% reduction). Costs associated directly with CEMRA in the pre-navigator group were $7000CAD (50 x $140CAD) and in the post-navigator group were $1960CAD (14 x $140CAD), a saving of $5040.
*CAD = Canadian dollars.
We conclude that using a free-breathing, ECG-triggered, navigator-gated 3D segmented steady state free precession (SSFP) sequence is a cost-effective way of imaging disease of the aorta without compromising imaging quality.
Number of CEMRA performed
Group 1 familial screening
Group 2 dilatation
Group 3 dissection
Group 4 aortic congenital disease
Group 5 vasculitis
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.